Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation
about
Understanding the interplay between host immunity and Epstein-Barr virus in NPC patientsDefining immune engagement thresholds for in vivo control of virus-driven lymphoproliferationStructural Mechanism of ER Retrieval of MHC Class I by CowpoxViral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolutionA negative feedback modulator of antigen processing evolved from a frameshift in the cowpox virus genome.Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and eliminationDifferences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus.Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipientsEpstein-Barr virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin-10 production from monocytesPersistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans.Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric CarcinomasThe "Bridge" in the Epstein-Barr virus alkaline exonuclease protein BGLF5 contributes to shutoff activity during productive infection.Epstein-Barr virus BGLF4 kinase downregulates NF-κB transactivation through phosphorylation of coactivator UXT.EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition.Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunitySNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expressionThe TAP translocation machinery in adaptive immunity and viral escape mechanisms.Evasion of adaptive and innate immune response mechanisms by γ-herpesviruses.The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-IICloning of the Epstein-Barr virus-related rhesus lymphocryptovirus as a bacterial artificial chromosome: a loss-of-function mutation of the rhBARF1 immune evasion gene.Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.Characterization of the subcellular localization of Epstein-Barr virus encoded proteins in live cells.Innate immune modulation in EBV infection.Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis.The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis.
P2860
Q26823898-C409868B-A0F0-46DC-AD74-56F20F744B7FQ27324746-64EB955C-92EE-4DD5-A60D-84E2A2D48D2CQ27675354-55697AF4-0FCB-45DD-B058-D519172BA6EBQ28083232-395AD53F-164C-41D4-B7F3-E4C91EED2DECQ30422739-5B2DCFF1-1FB1-4D33-BAAC-6537B94B427FQ33799067-518662C2-3BBE-4B63-B8D9-F7464672E9A2Q34277034-8C0D8D67-145E-4F81-BB43-14A0C4F1C650Q34720273-949A054B-227F-4E61-820E-EC0E1FD79D48Q34742133-E70D0609-7F41-422D-BB6B-A238B13F94D3Q34769696-650729EB-E6D1-4C98-87C0-7124D162171DQ35077651-4EB3E564-1E54-4E35-B5F4-4D852F2307CBQ35531669-9F542004-27A2-4CCC-9297-DC19B8F2E684Q35665981-A8CA2E93-DE91-4736-8EE8-CB12BB7651D4Q35672979-2F2AE8E8-DFEA-48D0-B415-F013D6744E6CQ35842145-11FA2474-0BC6-4A2C-A52D-BC45C7E0ADCCQ36080810-CEADD8AB-A73A-4B6F-A44A-C2FB188E8FD7Q36154936-F7087769-D48F-45C5-B181-AADC648F4324Q36363901-F9793D27-35C2-46B1-8021-655DF4848F1FQ36590231-55B237EC-8FA7-43C3-8654-ABAE5089BE44Q37369220-494FBA4A-FA89-4233-9FA8-79085E0D0F2FQ37469949-4AFF7336-2850-4D0B-95D2-E3291D0A6363Q37652046-9FAAF360-44DA-4BAB-8A09-7CDF81C468BDQ37697107-A95FFC9C-2554-4D32-8CD8-60B01BDD1B27Q37941760-751495A0-9135-4616-86A5-AB4EA4D0C856Q38111863-5EB77296-336F-4110-B949-58572D2A18B3Q38827812-549A5106-912C-40D2-88C4-60E3B0A2B37EQ39630573-B4C0DD4E-CFBF-46C2-A3BF-87AAD408255BQ40955418-28D7DFC8-2C76-4ACE-AEFB-FF7748326B2EQ41807836-D28108F0-C1C5-4EA9-AACF-BD58410FEDE3Q42378401-F172C2E1-93B9-4739-AECB-E2B5F3D4D35CQ42702857-4AE77E73-809E-413A-92B1-D89ED84E055EQ45077858-524F65C9-4D68-4E5C-8D2E-E01460B04DE3Q54245037-1CFD0235-8452-4880-A5E0-A8441D76094E
P2860
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Specific targeting of the EBV ...... estricted antigen presentation
@ast
Specific targeting of the EBV ...... estricted antigen presentation
@en
Specific targeting of the EBV ...... estricted antigen presentation
@en-gb
Specific targeting of the EBV ...... estricted antigen presentation
@nl
type
label
Specific targeting of the EBV ...... estricted antigen presentation
@ast
Specific targeting of the EBV ...... estricted antigen presentation
@en
Specific targeting of the EBV ...... estricted antigen presentation
@en-gb
Specific targeting of the EBV ...... estricted antigen presentation
@nl
prefLabel
Specific targeting of the EBV ...... estricted antigen presentation
@ast
Specific targeting of the EBV ...... estricted antigen presentation
@en
Specific targeting of the EBV ...... estricted antigen presentation
@en-gb
Specific targeting of the EBV ...... estricted antigen presentation
@nl
P2093
P50
P356
P1476
Specific targeting of the EBV ...... estricted antigen presentation
@en
P2093
Alan B Rickinson
Andrew D Hislop
Daniëlle Horst
Daphne van Leeuwen
Emmanuel J H J Wiertz
Maaike E Ressing
P304
P356
10.4049/JIMMUNOL.0803218
P407
P577
2009-02-15T00:00:00Z